The University of British Columbia Board of Governors

Similar documents
CAROLINA EXPRESS USER GUIDE

Negotiating Series A Term Sheets

INTELLECTUAL PROPERTY POLICY

TRANSLATIONAL GENOMICS RESEARCH INSTITUTE INTELLECTUAL PROPERTY POLICY 1, 2

RUTGERS POLICY PATENT POLICY OF RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY

Intellectual Property Policy

TERM SHEET FOR MACH37 PARTICIPATION AND FINANCING OF [COMPANY NAME] [DATE], 2016

Kyushu University: Rules on the Handling of Intellectual Property

Negotiating Series A Term Sheets

Johns Hopkins University. Policy on Individual Financial Interests and Financial Conflict of Interests 1, 2 in Research

PART TWO, CHAPTER XII INTELLECTUAL PROPERTY

APPENDIX D. PATENT AND COPYRIGHT POLICY The Texas State University System

NORTH CAROLINA AGRICULTURAL AND TECHNICAL STATE UNIVERSITY

Venture Capital Term Sheet (Long Form) The form is very pro-investor oriented.

Portage Biotech Inc. Consolidated Interim Financial Statements For the three months ended June 30, 2014 Unaudited Prepared by Management

Appendix A: Sample Term Sheet*

Portage Biotech Inc. Consolidated Interim Financial Statements. For the three and nine months ended December 31, 2014 Unaudited Prepared by Management

Negotiating Term Sheets Michael Weiner April 20, 2017

Forms of Business Organization in Canada

SALK INSTITUTE FOR BIOLOGICAL STUDIES PATENT AND INVENTION POLICY

Forms of Business Organizations in Canada

SUMMARY OF SHAREHOLDER RIGHTS AND IMPORTANT ASPECTS IN WHICH THE COMPANY S CONDUCT DEVIATES FROM THE SWEDISH CORPORATE GOVERNANCE CODE

[NAME OF COMPANY] SUMMARY OF TERMS SERIES A PREFERRED STOCK FINANCING ([DATE])

The University of British Columbia Board of Governors

WHEATON PRECIOUS METALS CORP. (formerly SILVER WHEATON CORP.) DIVIDEND REINVESTMENT PLAN

SQUIRE MINING LTD. (An Exploration Stage Company) CONDENSED INTERIM FINANCIAL STATEMENTS. For the three months ended January 31, 2018

Portage Biotech Inc. Consolidated Interim Financial Statements. For the three and six months ended September 30, 2016 Unaudited Prepared by Management

PROJECT FINANCE CORP.

Condensed Interim Consolidated Financial Statements. For the Six Months Ended March 31, (Expressed in Canadian Dollars)

CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS FOR THE THREE AND SIX MONTHS ENDED MARCH 31, 2017 AND 2016 (EXPRESSED IN CANADIAN DOLLARS)

Report for the Three Months Ended December 31, 2011 and 2010

Portage Biotech Inc. Consolidated Interim Financial Statements. For the three months ended June 30, (Unaudited Prepared by Management)

CONSOLIDATED FINANCIAL STATEMENTS. DECEMBER 31, 2008 and (Expressed in U.S. Dollars)

THE KEG ROYALTIES INCOME FUND

ENABLENCE TECHNOLOGIES INC.

ACCELERANT VENTURES, L.P. AUGUST, (the Company ) a. The closing is expected to occur on or before, 2014 (the Closing ).

CANADA COAL INC. CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED SEPTEMBER 30, 2017 AND 2016 (EXPRESSED IN CANADIAN DOLLARS)

FSB REVISION OF THE INTELLECTUAL PROPERTY POLICY AND PATENT POLICY. Date of First Reading: Date of Second Reading: Tanja Steigner, Chair

Corporate Venture Capital: Structuring Concerns for Investors and Startups

Pirelli Intellectual Property Policy (or IPR) INTRODUCTION

REPORT TO THE BOARD OF GOVERNORS

RETURN OF SERVICE CONTRACT

VENTURE CAPITAL INVESTMENTS

INCOME FUND THE BDC INCOME FUND. PROSPECTUS November 24, Advised by: Full Circle Advisors, LLC

Joint Ventures: 25 FAQs - a guide for CEOs and CFOs

Consolidated Financial Statements. Intrinsyc Software International, Inc. August 31, 2005

Dalhousie University Staff Pension Plan. Statement of Investment Policies and Guidelines of the Dalhousie Pension Trust Fund

WHEREAS: In consideration of the mutual promises and covenants contained herein, the parties hereto agree as follows:

annotated term sheet

Shoppers Drug Mart Corporation Condensed Consolidated Statements of Earnings (unaudited) (in thousands of Canadian dollars, except per share amounts)

Technology Transfer Office as a Business Unit

ALEXANDRA CAPITAL CORP.

SQUIRE MINING LTD. (An Exploration Stage Company) CONDENSED INTERIM FINANCIAL STATEMENTS. For the six months ended April 30, 2018

CANADA COAL INC. CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED SEPTEMBER 30, 2012 AND 2011 (EXPRESSED IN CANADIAN DOLLARS)

Auditors Report and Consolidated Financial Statements of BRIDGES.COM INC. November 30, 2001 and 2000

Consolidated financial statements. Emblem Corp. [formerly Saber Capital Corp.] December 31, 2016 and 2015

Capella Education Company Code of Business Conduct COMPLIANCE WITH LAWS AND ETHICAL STANDARDS

VENTURE CAPITAL MOCK NEGOTIATION October 22, 2007

THE KEG ROYALTIES INCOME FUND Y E A R E N D R E P O R T

GREENVILLE HEALTH SYSTEM POLICY AND PROCEDURES Manual of Policy Directives POLICY NAME: Greenville Health System

GT Gold Corp. (Formerly Manera Capital Corp.) Consolidated Financial Statements December 31, 2016 and 2015 (Expressed in Canadian Dollars) (audited)

Joint Ventures and Strategic Alliances: Key Considerations for Negotiation, Structuring & Drafting Terri Krivosha Maslon LLP

JACKPOT DIGITAL INC. (formerly Las Vegas From Home.com Entertainment Inc.)

GLANCE TECHNOLOGIES INC.

THIS DOCUMENT MAY NOT BE DISTRIBUTED OR RELEASED IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES.

ATS Automation Tooling Systems Inc. For the year ending March 31, 2004

Conflict of Interest Policy for Research Investigators

Intellectual Property Policy

Cannabis Growth Opportunity Corporation

ALEXANDRA CAPITAL CORP. (An Exploration Stage Company)

Financial Statements of. For the years ended December 31, 2015 and December 31, (Expressed in Canadian Dollars)

MUTUAL FUND SERIES TRUST GLOBAL DIVIDEND OPPORTUNITIES FUND. STATEMENT OF ADDITIONAL INFORMATION September 27, 2017

REDLINE RESOURCES INC.

SUBSCRIPTION AND SHAREHOLDERS' AGREEMENT

THE KEG ROYALTIES INCOME FUND S E C O N D Q U A R T E R R E P O R T

Negotiating Term Sheets Michael Weiner April 12, 2018

Deans Knight Income Corporation. Interim Financial Statements June 30, 2014 (Unaudited)

Portage Biotech Inc. (Formerly known as Bontan Corporation Inc.)

Licensing Issues in the Life Sciences Industry: Negotiating University License Agreements

DIVERSIFIED ROYALTY CORP. Annual Information Form For the year ended December 31, 2017

PACIFIC HARBOUR CAPITAL LTD. (formerly Venture Pacific Development Corp.) (Translation of registrant s name into English)

Liquor Stores Income Fund

Unaudited Condensed Interim Consolidated Financial Statements. HLS Therapeutics Inc. For the Three Months Ended March 31, 2018

How to Prepare an Initial Public Offering

BRAVURA VENTURES CORP. CONDENSED INTERIM FINANCIAL STATEMENTS FOR THE THREE MONTHS ENDED APRIL 30, 2017 AND 2016 (EXPRESSED IN CANADIAN DOLLARS)

ALEXANDRA CAPITAL CORP. (An Exploration Stage Company)

DIVIDEND REINVESTMENT PLAN

Portage Biotech Inc. Consolidated Interim Financial Statements. For the three and nine months ended December 31, 2018

ABC: Up to $5,000,000 XYZ: Up to $8,000,000 Others: between $2 and $4 million

Pacific Ridge Exploration Ltd.

Biomarkers Consortium General Intellectual Property and Data Sharing Principles

Canoel International Energy Ltd. Consolidated Financial Statements As at and for the years ended March 31, 2012 and 2011

ALPHACIPHER ACQUISITION CORPORATION

FRONT STREET TACTICAL BOND CLASS

CanWel Building Materials Income Fund

BOSTON PIZZA ROYALTIES INCOME FUND AND BOSTON PIZZA INTERNATIONAL INC. ANNOUNCE THIRD QUARTER RESULTS AND OCTOBER DISTRIBUTION TO UNITHOLDERS

Consolidated Financial Statements (Expressed in Canadian dollars) Mountain Province Diamonds Inc.

Kew Media Group Inc. First Quarter 2017 Interim Report to Shareholders

DDJ CANADIAN HIGH YIELD FUND

1. benefit all generations of endowment beneficiaries equally by maintaining the purchasing power of endowment capital over time;

Transcription:

The University of British Columbia Board of Governors Policy No.: 105 Approval Date: November 2000 Last Revision: Responsible Executive: Vice-President, Administration and Finance Vice-President, Research Title: Acceptance, Management and Sale of Technology Licensing Equity Background & Purposes: To establish guidelines for the University concerning equity transactions related to University technology companies, management of the equity in those companies and to ensure a fair distribution of the proceeds from liquidated equity holdings to benefit the University as a whole. 1. General 1.1. Transfer by the University of its rights in an invention(s) to investor(s) by way of a licence agreement may include the provision for the University to receive an equity position in a technology company. 1.2. A decision to take an equity position requires prior consultation with the inventors to enable understanding of the nature of the equity transaction and ensuring the opportunity to obtain independent legal and tax advice. Each inventor is required to provide the University-Industry Liaison Office ( UILO ) with a full disclosure of his/her relationship with the company in which equity forms all or a part of any financial arrangement with the University. 1.3. The UILO is responsible for the negotiation of technology equity transactions. 1.4. The Technology Equity Management Committee is responsible for the management of the University s equity in technology companies governed by this policy. 1

PROCEDURES Approved: November 2000 Pursuant to Policy #1: Administration of Policies, "Procedures may be amended by the President, provided the new procedures conform to the approved policy. Such amendments are reported at the next meeting of the Board of Governors and are incorporated in the next publication of the UBC Policy and Procedure Handbook." 1. Inventor Consultation and Disclosure 1.1. Prior consultation with the inventors is required to ensure that they understand the nature of the equity transaction. In addition the following is required: 1.1.1. Each inventor is required to provide the UILO with a full disclosure of his/her relationship with the company. This includes equity held in the company, positions held on company boards, as an officer or employee of the company, or any private consulting arrangements with the company; 1.1.2. Confirmation that they have been advised to seek independent legal and tax advice in relation to the equity transaction. The cost of any independent legal or tax advice will be borne by the inventor. 1.2. Where inventors choose to be directly compensated by the company, they will be required to waive their rights to share in equity or royalties received by the University. In such cases, the University will pro-rate the level of compensation required under the licence agreement to net out the inventor s share. 2. Structuring Equity Transactions 2.1. The University s equity position shall be in consideration of the intellectual property assigned or licensed to the company. In any arrangement full consideration shall be given 2.1.1. to securing anti-dilution provisions through the achievement of milestones related to a predetermined level of investment, cumulative sales revenue, or initial public offering (IPO) with dilution of the University s equity position being linked to acquisition of additional capital; 2.1.2. the exercise by the University of its right to invest in follow-on rounds of financing; 2.1.3. price protection or anti-dilutive provisions to guard against dilution that may occur through a subsequent financing at reduced share prices; 2.1.4. to obtaining piggy-back registration rights to enable the future sale of the equity. 2.1.5. University representation on the Board of Directors through a seat on the board, observer status at board meetings, or full copies of all material distributed to the board and minutes of board meetings. In cases where the University has a board seat, the University shall provide a written request to the University s nominee thereby invoking the University insurer s coverage for that individual. Any fees, options, or shares received as compensation for attending board meetings shall be deemed compensation to the University. 2

3. Distribution of Equity 3.1. Equity shall be distributed as soon as possible to co-licensors (i.e. affiliated hospitals) and inventors subject to: 3.1.1. Any pooling, hold or escrow restrictions; 3.1.2. Securities regulations; and 3.1.3. Holdbacks for covering the direct costs of the transaction. 3.2. Following the distribution of equity, it shall be the sole responsibility of the inventor(s) to manage the inventor(s) shares and to comply with any tax, legal or contractual obligations associated with the distribution, ownership or disposition of the inventor(s) shares. 3.3. Share certificates shall be forwarded to UBC Treasury at the earliest opportunity for recording, distribution, management and safekeeping. 4. Distribution of Net Revenue 4.1. In respect of each technology covered by this policy 4.1.1. Net Revenue earned by the University from its share of equity after the foregoing distribution will be distributed as follows: 4.1.1.1. 25% to the Inventor s faculty 4.1.1.2. 75% to University General Revenue 5. Due Diligence Consideration by the Board of Governors 5.1. Any transaction under this policy that requires Board approval shall be accompanied by a certificate from an independent third party nominated by the UILO indicating that the value of the consideration received by the University is commensurate with the value of the rights granted by the University. In respect of all other transactions, an annual summary will be given to Board disclosing the technology company, the equity held, and the technology given as consideration. 6. Taxation Considerations 6.1. As legally required by Revenue Canada, the University will file an information return in the form of a T4 with respect to the value of shares transferred to researchers who are employees or former employees. Payment to employees or former employees or non-resident shall be contingent on 6.1.1. the withholding of amounts in respect of income tax, Canada Pension Plan contributions and Employment Insurance contributions as may be required; 6.1.2. employees and former employees will only be required to include the value of shares in income in the year that they are received from the University; 6.1.3. the value of the shares should be determined as of the date that the shares are transferred to the employee or former employee; 3

6.1.4. if the researchers are students with no employment relation to the University, then the University will be responsible to issue a T4A slip to the student; 6.1.5. if the value of the equity is uncertain it is the responsibility of the University to have the equity valued by a qualified valuator using accepted valuation techniques. In situations where the equity is privately held and has an established fair market value, the researchers may be placed in a situation where taxes are payable on the value of the equity, yet there exists no market for the equity. Inventors should consider detailed tax planning to minimize the tax consequences of these transactions; 6.1.6. other lawful requirements of Revenue Canada 7. Relationship Management 7.1. Acting for the University as shareholder in and of university licensed technology company under this policy, UILO shall 7.1.1. exercise all voting shares and exercising other shareholder rights such as attending the company annual general meeting, waivers of pre-emptive rights, etc. shall be the responsibility of the UILO; 7.1.2. monitor company performance and adherence to the terms of the licensing provisions; 7.2. However, UILO s authority is limited to standard transactions. Issues of a precedent setting nature or that exceed $500,000 in value shall be managed in accordance with UBC signing resolution #8 - Research. 7.3. If a member of the University community is requested by the University to serve as a member of the Board of Directors of the company, then any options or shares that that individual receives as compensation for his/her services on the Board shall be transferred to the University. 8. Conflict of Interest 8.1. The Board s conflict of interest policy (#97) applies. The University s decision to take equity in a company creates the potential for conflicts of interest for both the University and the researchers. 8.2. Where in the subsequent licensing of other University technology to the company in which the University is already a shareholder, the University must carefully consider whether it is receiving fair consideration for the second technology and whether the transaction is being affected by the fact that it is already a shareholder in the licensee company. 8.3. Where a researcher has a substantive role in the operation of the company (as a founder, officer, director, shareholder, or consultant), the University needs to ensure that it has received full disclosure of the researcher s interests in the company. It must also ensure that there is a mechanism to manage ongoing disclosure of new technologies and improvements to existing technologies. 9. Insider Trading 9.1. Insiders are those who are in a special relationship with a reporting issuer and includes all persons who may receive or have access to confidential information. Insiders of a company are: 9.1.1. directors, officers and employees of the company, its parent company and/or its subsidiaries; 4

9.1.2. persons who are outsiders of the company including persons that are engaged in or proposing to engage in any business or professional activity with or on behalf of the company ; 9.1.3. employees of the University who are engaged in or who proposed to engage in research and development of the technology licensed to a reporting issuer would be an insider of the reporting issuer. 9.2. Insider status continues even after the business relationship between the employee and the reporting issuer has been terminated if the inside information existed prior to termination of the business relationship. 10. UBC Staff as Shareholders 10.1. The Vice-President, Research shall develop guidelines, to be approved by the Board, that will apply to investments by UBC staff members in licensees of University technology. 11. Definitions 11.1. Equity includes shares of stock, and also other forms of securities such as warrants, options, share appreciation rights, and interests in limited partnerships, private or publicly traded companies. 11.2. Net Revenue is calculated as: 11.2.1. gross revenue from liquidated equity and dividends 11.2.1.1. Less uncovered direct costs of patenting, prototype development, and licensing legal fees 11.2.1.2. Less 15% of the balance remaining after deduction (1) to be used in support of UILO operations 11.2.1.3. Less any distributions to co-licensors (which are generally calculated as a percentage of the balance remaining after deduction (1)). 5